LONG-TERM SURVIVAL OF 4 DOGS WITH DISSEMINATED ASPERGILLUS-TERREUS INFECTION TREATED WITH ITRACONAZOLE

被引:39
作者
KELLY, SE
SHAW, SE
CLARK, WT
机构
[1] School of Veterinary Studies, Murdoch University, Western Australia
关键词
D O I
10.1111/j.1751-0813.1995.tb03562.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Four dogs with disseminated aspergillosis caused by Aspergillus terreus were treated with oral itraconazole for 190 to 1095 days, Infection was eliminated in 1 dog. Two dogs were treated for 1000 and 1095 days but were eventually euthanased 572 and 485 days after treatment was stopped. At necropsy both dogs had widespread aspergillosis. The fourth dog was euthanased for other reasons after 190 days of treatment when it was showing a good clinical response although there was radiographic evidence that the disease was progressing.
引用
收藏
页码:311 / 313
页数:3
相关论文
共 21 条
[1]   AZOLE ANTIFUNGAL AGENTS [J].
BODEY, GP .
CLINICAL INFECTIOUS DISEASES, 1992, 14 :S161-S169
[2]  
DALLMAN MJ, 1992, J AM VET MED ASSOC, V200, P511
[3]   DISSEMINATED ASPERGILLOSIS IN DOGS [J].
DAY, MJ ;
PENHALE, WJ ;
EGER, CE ;
SHAW, SE ;
KABAY, MJ ;
ROBINSON, WF ;
HUXTABLE, CRR ;
MILLS, JN ;
WYBURN, RS .
AUSTRALIAN VETERINARY JOURNAL, 1986, 63 (02) :55-59
[4]   IMMUNOLOGICAL STUDY OF SYSTEMIC ASPERGILLOSIS IN GERMAN SHEPHERD DOGS [J].
DAY, MJ ;
EGER, CE ;
SHAW, SE ;
PENHALE, WJ .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1985, 9 (04) :335-347
[5]   FUTURE-DIRECTIONS OF ANTIFUNGAL CHEMOTHERAPY [J].
GRAYBILL, JR .
CLINICAL INFECTIOUS DISEASES, 1992, 14 :S170-S181
[6]   UNITED-STATES EXPERIENCE WITH ITRACONAZOLE IN ASPERGILLUS, CRYPTOCOCCUS AND HISTOPLASMA INFECTIONS IN THE IMMUNOCOMPROMISED HOST [J].
HOSTETLER, JS ;
DENNING, DW ;
STEVENS, DA .
CHEMOTHERAPY, 1992, 38 :12-22
[7]   THE PATHOLOGY OF DISSEMINATED ASPERGILLUS-TERREUS INFECTION IN DOGS [J].
KABAY, MJ ;
ROBINSON, WF ;
HUXTABLE, CRR ;
MCALEER, R .
VETERINARY PATHOLOGY, 1985, 22 (06) :540-547
[8]  
KAUFMAN AC, 1994, J AM ANIM HOSP ASSOC, V30, P132
[9]  
MARKS DL, 1983, CANINE PRACT, V10, P49
[10]  
MORI T, 1992, Chemotherapy, V38, P53